RP-6306, a highly selective inhibitor of this target, was tested on several ovarian carcinoma cell lines and showed greater toxicity in CCNE1 amplified preclinical models alone or with gemcitabine[104]. Here, CCNE1 is linked to ovarian carcinoma.